Suppr超能文献

长期甲状腺替代治疗与脂蛋白(a)及其他脂蛋白水平

Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins.

作者信息

Pazos F, Alvarez J J, Rubiés-Prat J, Varela C, Lasunción M A

机构信息

Servicio de Endocrinología, Hospital Ramón y Cajal, Madrid, Spain.

出版信息

J Clin Endocrinol Metab. 1995 Feb;80(2):562-6. doi: 10.1210/jcem.80.2.7852521.

Abstract

There is a general interest to know whether lipoprotein(a) [Lp(a)] is under hormonal control. Hypothyroidism is a well known cause of secondary hyperlipidemia, which mainly affects low density lipoprotein (LDL) cholesterol levels, but the result on the effects of L-T4 replacement therapy on the Lp(a) concentration is controversial. We studied 12 severely hypothyroid, hypercholesterolemic patients under basal conditions and during L-T4 treatment. We found a rapid decrease in both LDL cholesterol (5.71 +/- 0.62 vs. 4.37 +/- 0.44 mmol/L basally and after 1 month of thyroid replacement, respectively) and apolipoprotein-B (Apo-B) levels (1.89 +/- 0.02 vs. 1.52 +/- 0.17 g/L, respectively); these changes persisted for up 1 yr of analytical euthyroidism and paralleled the improvement in the thyroid status of the patients. In contrast, the plasma Lp(a) concentration did not change at any time (496 +/- 123, 464 +/- 128, and 441 +/- 110 mg/L under basal conditions and after 1 and 14-15 months of thyroid replacement, respectively), and the small fluctuations observed in some patients did not correlate with those in LDL cholesterol or Apo-B, and were not associated with any particular Apo(a) phenotype. In relation to HDL fractions, high density lipoprotein3 (HDL3) remained stable, but HDL2 cholesterol and phospholipid levels decreased during treatment, changes that were the inverse of those in postheparin plasma hepatic lipase activity. Patients in the present study were normotriglyceridemic, except one who was hypertriglyceridemic at diagnosis, but even in this patient, triglyceride levels were unaffected by T4 substitution therapy, as was postheparin plasma lipoprotein lipase activity. The changes observed in LDL, HDL2, and hepatic lipase activity delineate the lipoprotein-related response to T4 replacement therapy, whereas potential individual fluctuations in Lp(a) levels are probably more dependent on other factors, such as the production rate, which are not affected by thyroid hormones.

摘要

人们普遍关注脂蛋白(a)[Lp(a)]是否受激素控制。甲状腺功能减退是继发性高脂血症的一个众所周知的原因,主要影响低密度脂蛋白(LDL)胆固醇水平,但左甲状腺素(L-T4)替代疗法对Lp(a)浓度影响的结果存在争议。我们研究了12例严重甲状腺功能减退、高胆固醇血症患者在基础状态下以及L-T4治疗期间的情况。我们发现LDL胆固醇(基础状态下为5.71±0.62 mmol/L,甲状腺替代治疗1个月后为4.37±0.44 mmol/L)和载脂蛋白B(Apo-B)水平(分别为1.89±0.02 g/L和1.52±0.17 g/L)均迅速下降;这些变化在甲状腺功能正常的分析状态下持续了1年,并与患者甲状腺状态的改善情况平行。相比之下,血浆Lp(a)浓度在任何时候都没有变化(基础状态下以及甲状腺替代治疗1个月和14 - 15个月后分别为496±123、464±128和441±110 mg/L),一些患者观察到的小波动与LDL胆固醇或Apo-B的波动无关,也与任何特定的Apo(a)表型无关。关于高密度脂蛋白(HDL)组分,高密度脂蛋白3(HDL3)保持稳定,但治疗期间HDL2胆固醇和磷脂水平下降,这些变化与肝素后血浆肝脂酶活性的变化相反。本研究中的患者除1例在诊断时为高甘油三酯血症外,其余均为正常甘油三酯血症,但即使在该患者中甘油三酯水平也不受T4替代疗法的影响,肝素后血浆脂蛋白脂肪酶活性也是如此。LDL、HDL2和肝脂酶活性的变化描绘了脂蛋白对T4替代疗法的反应,而Lp(a)水平潜在的个体波动可能更多地取决于其他因素,如产生率,而这些因素不受甲状腺激素的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验